AMENDMENTS TO THE CLAIMS:

1-43. (Canceled)

44. (Previously presented) A cell which expresses at least two proteinaceous membrane-bound chimeric receptors,

the first of said receptors comprising (a) an extracellular portion which is capable of specifically recognizing and binding a target cell or a target infective agent, (b) a transmembrane portion derived from a T cell receptor, a B cell receptor, or an Fc receptor protein which, in the absence of an intracellular signalling domain, is capable of signalling said cell to destroy a receptor-bound target cell or a receptor-bound target infective agent, and (c) an intracellular domain that does not signal said cell to destroy a receptor-bound target cell or receptor-bound target infective agent; and

the second of said receptors comprising (a) an extracellular portion which is capable of specifically recognizing and binding said target cell or said target infective agent, and (b) an intracellular portion which is derived from CD28.

45. (Original) The cell of claim 44, wherein, following binding of said extracellular portion to said cell or agent, said transmembrane portion oligomerizes with a cytolytic signal-transducing protein of said receptor-bearing cell resulting in destruction of said receptor-bound agent or cell.

46. (Original) The cell of claim 44, wherein said binding is MHC-independent.

47. (Original) The cell of claim 44, wherein said transmembrane portion comprises an oligomerizing portion of a T cell receptor protein, a B cell receptor protein, or an Fc receptor protein, or a functional derivative thereof.

48-50. (Canceled)

51. (Previously presented) The cell of claim 101, wherein said T cell receptor protein is ζ.

52. (Previously presented) The cell of claim 51, wherein said chimeric receptor comprises amino acids 400-420 of SEQ ID NO:6.

53-71. (Canceled)

72. (Previously presented) The cell of claim 44, wherein said extracellular portion comprises the ligand-binding portion of a receptor, the receptor-binding portion of a ligand, the antigen-binding portion of an antibody, or a functional derivative thereof.

73. (Previously presented) The cell of claim 44, wherein said target infective agent is an immunodeficiency virus or said target cell is a host cell infected with an immunodeficiency virus.

74. (Original) The cell of claim 73, wherein said extracellular portion comprises an HIV envelope-binding portion of CD4, or a functional derivative thereof.

75. (Original) The cell of claim 73, wherein said HIV-envelope binding portion of CD4 comprises the peptide encoded by nucleotides 1-369 of SEQ ID NO:1.

76-78. (Canceled)

79. (Previously presented) A cell which expresses at least two proteinaceous

membrane-bound chimeric receptors,

the first of said receptors comprising (a) an extracellular portion which is capable of specifically recognizing and binding a target cell or a target infective agent, and (b) a transmembrane portion derived from a T cell receptor CD3, zeta, or eta polypeptide, a B cell receptor, or an Fc receptor, and (c) an intracellular domain that does not signal target cell or target infective agent destruction; and

the second of said receptors comprising (a) an extracellular portion which is capable of specifically recognizing and binding said target cell or said target infective agent, and (b) an intracellular portion which is derived from CD28.

80-99. (Canceled)

100. (Currently amended) The cell of claim 44, ~~92, or 93,~~ wherein said cell destroys said receptor-bound target cell or target infective agent by cytolysis.

101. (Previously presented) The cell of claim 44, wherein said transmembrane portion of the first of said receptors is derived from a T cell receptor protein.